Status:
RECRUITING
Biocollection of Patients With ANCA Associated Vasculitis
Lead Sponsor:
University Hospital, Brest
Conditions:
ANCA-associated Vasculitis
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
As rare disease, vasculitis affects a small number of patients, the cohorts available in the literature are few and the pathophysiological mechanisms remain to be elucidated. The collection of standar...
Detailed Description
Vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA) is a group of rare and severe autoimmune diseases, encompassing several entities: granulomatosis with polyangiitis (GPA), microsc...
Eligibility Criteria
Inclusion
- Major patients with no upper age limit.
- Patients assessed as part of the reference centre for rare autoimmune diseases at the CHRU in Brest.
- Patients for whom a diagnosis of ANCA-associated vasculitis is made by the physician in charge of the patient, according to the definitions of the Chapel-Hill Consensus Conference.
- Patient affiliated with Social Security
- Patient who has signed written informed consent
Exclusion
- Minor
- Patients unable to consent.
- Patients refusing to participate in research
- Patient under legal protection (tutelage, curatorship)
- Pregnant or lactating women
- Hemoglobin (Hb) \< 7g/dL
Key Trial Info
Start Date :
October 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 27 2032
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05364892
Start Date
October 27 2022
End Date
October 27 2032
Last Update
August 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest - Service de rhumatologie
Brest, France, 29200